1. In Vivo

Changing Italian Hospital Distribution: NGC Assumes Risk to Gain Reward

Italy has become the most favored European point-of-entry for many US device start-ups. NGC Medical, Italy's leading hospital distributor, is responding to hospitals' needs to shift the risk burden to maintain the pace of cardiovascular innovation.

by Stephen Levin

For many US cardiovascular device executives, Italy has replaced Germany and France as the most attractive entry point into the European hospital market. In part this is due to problems facing those other nations' health care systems, such as the significant financial constraints that have dramatically reduced reimbursement levels in Germany

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.